Trial Outcomes & Findings for Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) (NCT NCT06360575)

Last Updated: 2026-05-04

Results Overview

ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among analyzable patients. Objective response is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Details about how to define complete response and partial response can be found in the master protocol. 90% two-sided binomial exact confidence interval is calculated for ORR.

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

PHASE2

Target enrollment

20 participants

Primary outcome timeframe

Tumor assessments occurred at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

Results posted on

2026-05-04

Participant Flow

Subprotocol C2 was activated on May 31, 2016. Twenty patients were enrolled on EAY131-C2 between July 20, 2016, and March 16, 2020. Sixteen patients were enrolled on the basis of the results from the NCI-MATCH assay and 4 on the basis of the outside assay results.

For subprotocol C2, patients were required to have MET Exon 14 deletion by the Oncomine® Assay RNA-sequencing approach, and confirmation was performed retrospectively at the DNA level using Anchored Multiplex PCR, utilizing a custom targeted DNA sequencing panel and analysis pipeline that permitted analysis of the MET exon 14 coding region and surrounding intronic sequences.

Participant milestones

Participant milestones
Measure	Treatment (Crizotinib) Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Overall Study STARTED	20
Overall Study Started Protocol Therapy	18
Overall Study Eligible, Treated and Mutation Status Confirmed	14
Overall Study COMPLETED	0
Overall Study NOT COMPLETED	20

Reasons for withdrawal

Reasons for withdrawal
Measure	Treatment (Crizotinib) Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Overall Study Ineligible or Never Started	6
Overall Study Adverse Event	2
Overall Study Death	3
Overall Study Disease Progression	7
Overall Study Withdrawal by Subject	1
Overall Study Physician Decision	1

Baseline Characteristics

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Treatment (Crizotinib) n=14 Participants Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Age, Continuous	68 years n=54 Participants
Sex: Female, Male Female	6 Participants n=54 Participants
Sex: Female, Male Male	8 Participants n=54 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=54 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	14 Participants n=54 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=54 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=54 Participants
Race (NIH/OMB) Asian	2 Participants n=54 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=54 Participants
Race (NIH/OMB) Black or African American	1 Participants n=54 Participants
Race (NIH/OMB) White	11 Participants n=54 Participants
Race (NIH/OMB) More than one race	0 Participants n=54 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=54 Participants

PRIMARY outcome

Timeframe: Tumor assessments occurred at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

Population: Eligible, treated and mutation status confirmed

Outcome measures

Outcome measures
Measure	Treatment (Crizotinib) n=14 Participants Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Objective Response Rate (ORR)	14.3 percentage of participants Interval 2.6 to 38.5

SECONDARY outcome

Timeframe: Assessed at baseline, then every 2 cycles for the first 26 cycles, and every 3 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined

Population: Eligible, treated and mutation status confirmed

Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.

Outcome measures

Outcome measures
Measure	Treatment (Crizotinib) n=14 Participants Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
6-month Progression Free Survival (PFS)	29 percentage of participants Interval 11.3 to 48.7

SECONDARY outcome

Timeframe: Assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

Population: Eligible, treated and mutation status confirmed

PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.

Outcome measures

Outcome measures
Measure	Treatment (Crizotinib) n=14 Participants Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Progression Free Survival	2.0 months Interval 1.4 to 4.1

Adverse Events

Treatment (Crizotinib)

Serious events: 13 serious events

Other events: 16 other events

Deaths: 20 deaths

Serious adverse events

Serious adverse events
Measure	Treatment (Crizotinib) n=18 participants at risk Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Blood and lymphatic system disorders Anemia	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Cardiac disorders Atrial fibrillation	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
General disorders Fatigue	16.7% 3/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Skin and subcutaneous tissue disorders Rash maculo-papular	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Gastrointestinal disorders Nausea	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Infections and infestations Lung infection	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Infections and infestations Urinary tract infection	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Infections and infestations Infections and infestations - Other, specify	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Investigations Alanine aminotransferase increased	16.7% 3/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Investigations Aspartate aminotransferase increased	11.1% 2/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Investigations Lymphocyte count decreased	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Musculoskeletal and connective tissue disorders Generalized muscle weakness	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Nervous system disorders Dizziness	11.1% 2/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Nervous system disorders Syncope	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasms benign, malignant and unspecified (incl cysts and polyps) -	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Respiratory, thoracic and mediastinal disorders Aspiration	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Respiratory, thoracic and mediastinal disorders Pneumonitis	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Respiratory, thoracic and mediastinal disorders Respiratory failure	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Vascular disorders Hypotension	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Vascular disorders Thromboembolic event	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).

Other adverse events

Other adverse events
Measure	Treatment (Crizotinib) n=18 participants at risk Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Blood and lymphatic system disorders Anemia	33.3% 6/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
General disorders Edema limbs	22.2% 4/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
General disorders Fatigue	44.4% 8/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Skin and subcutaneous tissue disorders Pruritus	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Skin and subcutaneous tissue disorders Rash maculo-papular	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Gastrointestinal disorders Constipation	22.2% 4/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Gastrointestinal disorders Diarrhea	22.2% 4/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Gastrointestinal disorders Dyspepsia	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Gastrointestinal disorders Nausea	66.7% 12/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Gastrointestinal disorders Vomiting	22.2% 4/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Gastrointestinal disorders Gastrointestinal disorders - Other, specify	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Infections and infestations Urinary tract infection	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Investigations Alanine aminotransferase increased	38.9% 7/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Investigations Alkaline phosphatase increased	27.8% 5/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Investigations Aspartate aminotransferase increased	27.8% 5/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Investigations Blood bilirubin increased	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Investigations Creatinine increased	16.7% 3/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Investigations Lymphocyte count decreased	16.7% 3/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Investigations Weight loss	11.1% 2/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Investigations White blood cell decreased	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Metabolism and nutrition disorders Anorexia	27.8% 5/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Metabolism and nutrition disorders Hyperglycemia	11.1% 2/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Metabolism and nutrition disorders Hypoalbuminemia	22.2% 4/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Metabolism and nutrition disorders Hypocalcemia	16.7% 3/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Metabolism and nutrition disorders Hypokalemia	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Metabolism and nutrition disorders Hypomagnesemia	11.1% 2/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Metabolism and nutrition disorders Hyponatremia	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Metabolism and nutrition disorders Hypophosphatemia	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Musculoskeletal and connective tissue disorders Generalized muscle weakness	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Musculoskeletal and connective tissue disorders Musculoskeletal and connective tissue disorder - Other, specify	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Nervous system disorders Dizziness	11.1% 2/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Nervous system disorders Dysgeusia	22.2% 4/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Nervous system disorders Peripheral sensory neuropathy	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Eye disorders Eye disorders - Other, specify	22.2% 4/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Respiratory, thoracic and mediastinal disorders Dyspnea	11.1% 2/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Respiratory, thoracic and mediastinal disorders Hoarseness	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Respiratory, thoracic and mediastinal disorders Respiratory, thoracic and mediastinal disorders - Other, specify	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).
Vascular disorders Thromboembolic event	5.6% 1/18 • Assessed every 28 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration. All patients enrolled were included in the all-cause mortality analysis. Eighteen patients were included in the toxicity analysis (excluding two who did not receive treatment).

Additional Information

Study Statistician

ECOG-ACRIN Cancer Research Group

Phone: 617-632-3012

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: LTE60